Platelets and Smooth Muscle Cells Affecting the Differentiation of Monocytes

Michelle W. Y. Williams*, Ann K. Guiffre, John P. Fletcher
Department of Surgery, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia

Abstract

Background: Atherosclerosis is characterised by the formation of plaques. Monocytes play a pivotal role in plaque development as they differentiate into foam cells, a component of the lipid core whilst smooth muscle cells (SMC) are the principal cell identified in the cap. Recently, the ability of monocytes to differentiate into a myriad of other cell types has been reported. In lieu of these findings the ability of monocytes to differentiate into SMCs/smooth muscle (SM)-like cells was investigated.

Method and Results: Human monocytes were co-cultured with platelets or human coronary aortic SMCs and then analysed to assess their differentiation into SMCs/SM-like cells. The differentiated cells expressed a number of SMC markers and genes as determined by immunofluorescence staining and quantitative polymerase chain reaction (qPCR). CD array analysis identified marker expression profiles that discriminated them from monocytes, macrophages and foam cells as well as the expression of markers which overlapped with fibroblast and mesenchymal cells. Electron microscopy studies identified microfilaments and increased amounts of rough endoplasmic reticulum indicative of the SM-like cells, fibroblasts.

Conclusions: In the appropriate environmental conditions, monocytes can differentiate into SM-like cells potentially contributing to cap formation and plaque stability. Thus, monocytes may play a dual role in the development of plaque formation and ultimately atherosclerosis.

Introduction

In Australia, an estimated 45,600 people died from cardiovascular disease (CVD) in 2011 representing 31% of deaths. The leading cause of CVD is atherosclerosis, a chronic inflammatory disease where the accumulation of lipids, inflammatory cells and foam cells lead to the development of atherosclerotic plaques. The potential of a plaque to rupture is determined by its stability which in turn is determined by the ratio of the lipid core to the fibrous cap, the more stable plaques containing a larger fibrous cap [22].

Monocytes are known to play a pivotal role in plaque development. These cells ingest excess lipid to form foam cells leading to the production of a lipid core, they also express effector molecules that are pro inflammatory, cytotoxic, chemotactic and release metalloproteinases (MMPs) that degrade the fibrous cap. This ultimately leads to plaque destabilisation and potential rupture [38].

Vascular SMCs (VSMC) are the cells traditionally associated with the fibrous cap. Growth factors and cytokines induce their proliferation and migration from the tunica media into the intima ultimately resulting in fibrous cap formation of the plaque. Studies have since shown that the SMCs/SM-like cells found in the cap could be VSMCs, fibroblasts and/or myofibroblasts [10,13].

Over the last decade there have been several studies which have reported that other cells aside from medial SMCs contribute to the development of the fibrous cap. Bone marrow progenitor cells were found to be the predominant cell in the neointima of atherosclerotic plaques. Circulating progenitor cells injected into atherosclerotic mice increased SMC accumulation and collagen whilst decreasing macrophage infiltration in late atherosclerotic plaques [47]. CD68 positive cells (monocyte myeloid marker) co-expressing CD34 (haemopoietic marker), collagen I as well as alpha SM actin (fibrocytes) were found in the fibrous cap and neo-collagen rich areas of carotid endarterectomy specimens [23]. In atherosclerosis monocytes may have a dual role in plaque morphology and participate not only in the formation of the lipid core but also the fibrous cap. Thus, these cells potentially have an atheroprotective role via the induction of plaque stability.

Although monocytes are traditionally known to differentiate into macrophage/microphage foam cells more recently they have been shown to differentiate into numerous other cell types. To date, research groups have cultured CD14+ monocytes and with the aid of growth factors have induced their differentiation into endothelial cells, epithelial cells, hepatocytes, keratinocytes, neuronal cells, adipocytes, osteoblasts, T cells, fibrocytes and myofibroblasts [3,5,6,20,26,44,43]. Similarly, studies have also reported the use of co-culture systems to induce monocytes to differentiate into neural cells, SM-like cells and cardiomyocytes [19,23]. Thus, CD14+ monocytes have the potential to function...
like progenitor cells as these studies have shown them to have a pluripotent nature.

More recently, it has been shown that monocyte derived fibrocytes (co-expression of CD34 and collagen I) were identified in the fibrous caps of atherosclerotic plaques [25]. The primary objective of this study was to develop an in vitro model representative of an atherosclerotic environment. The secondary objective was to assess the potential of monocytes to further differentiate into SMC/SM-like cells via fibrocytes.

To mimic an atherosclerotic environment, human aortic SMCs were selected as in atherosclerosis there is an ongoing wound healing process that occurs whilst the damaged endothelium is being repaired. As part of this process, SMCs/myofibroblasts create the fibrous cap that encapsulates the plaque and separates the thrombotic components of the lipid core from the blood [23]. Platelets were also selected as they play a major role in wound healing by providing the haemostatic plug (part of the initial process of inflammation), which occurs when the endothelium of the arteries are damaged [43]. The platelets produce several growth factors and cytokines responsible for cell differentiation including; Platelet Derived Growth Factor beta beta (PDGFBB), transforming growth factor beta-1 (TGFβ1), epithelial growth factor (EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and insulin growth factor (IGF) [15].

The differentiation of monocytes into SMC/SCM-like cells was investigated using changes in protein and molecular expression as well as differences in cellular structure.

Methods

Ethics statement for obtaining the monocytes and platelets: Written consent was obtained for each cell sample and was ethically approved by the Western Sydney Local Health District Ethics Committee. Ethics number: JH/JL HREC2004/4/4.11 (2839).

The donation of the HcaSMCs was a cell line from ATCC, catalogue number: ATCC® CRL-1999.

Cell Culture Systems

Isolation of monocytes and platelets. Peripheral blood was collected from healthy volunteers. Consent was provided by each volunteer and approval for the study was granted by the Western Sydney Local Health District Research Ethics Committee. The platelets were obtained by centrifuging sodium citrate collection tubes at 120g for 10 minutes and the platelet rich plasma (PRP) collected. The PRP was centrifuged at 1550g, the supernatant removed and the platelets resuspended in PBS (calcium and magnesium free) (Invitrogen, NY USA). Platelet activation was confirmed by flow cytometry for increases in CD62P expression (data not shown). The remaining blood was diluted with the same volume of PBS, underplayed with LymphoprepTM 1.077 (Nycomed Pharma AS, Oslo, Norway) and spun at 300g. The buffy layer was then collected and monocytes isolated using the CD14 MACS microbeads (Miltenyi Biotec, Germany) system. The average monocyte purity obtained using this isolation method as assessed by FACScan flow cytometer (Becton Dickinson, NJ, USA) was >95%.

Human Coronary Aortic Smooth Muscle Cells (HcaSMC) were grown in smooth muscle supplement media and 10% FBS (Invitrogen, NY, USA).

Co-culture models. Monocytes were co-cultured with HcaSMC (M+SMC) or platelets (M+P) with their respective controls being cultured monocytes using the conditions described below. All cultures were incubated at 37°C and 5% CO2.

Monocytes. Monocytes were all cultured on a fibronectin (5 µg/cm²) coated surface in DMEM with the addition of 20 IU/ml penicillin G, 200mg/ml streptomycin, 2mM L-glutamine (Invitrogen, NY, USA) and 10% autologous serum at a concentration of 2.5×10⁵ cells/600 µl of media.

Cultured HcaSMC (M+SMCs). HcaSMC were placed in a 0.4 µm pore Transwell (Corning Costar, MA, USA) at a final concentration of 5×10⁵/100 µl of media to give a final ratio of monocytes to SMC of 50:1.

Cultured Platelets (M+Ps). Platelets were prepared at a final concentration of 2.5×10⁴ cells/10 µl of PBS and placed in a 0.4 µm pore Transwell containing 90 µl media to give a final ratio of monocytes to platelets of 1:800.

Immunofluorescence and Confocal Analysis

For immunofluorescence, the monocytes were cultured on fibronectin coated glass coverslips which were inserted into the tissue culture plates. On days 7 and 14 the cells were fixed with absolute methanol (Sigma Aldrich, St Louis, MI, USA).

Immunofluorescence staining. The Transwells were removed and the monocytes rehydrated by the addition of Tris-Buffered Saline (TBS) (Sigma Aldrich, St Louis, MI, USA) for 5 minutes. The coverslips were then removed from the cell culture plates and placed on Superfrost®-Plus poly-L-lysine coated slides

Table 1. List of antibodies used for staining. (N/A = no designation for clone).

| Antibody               | Clone     | Isotype | Host   | Dilution | Supplier       |
|------------------------|-----------|---------|--------|----------|----------------|
| CD34                   | H-140     | IgG     | Rabbit | 1:50     | Santa Cruz     |
| Procollagen I          | M-58      | IgG     | Rat    | 1:200    | Santa Cruz     |
| α-Smooth Muscle Actin  | α-sm-1    | IgG2a   | Mouse  | 1:50     | Novoceastra    |
| Calponin               | CALP      | IgG1    | Mouse  | 1:50     | DAKO           |
| Mouse IgG1             | Universal | N/A     | Mouse  | 1:50     | DAKO           |
| Rabbit Universal IgG   | Universal | N/A     | rabbit | neat     | DAKO           |
| Rat IgG1k              | KLH-G1-2-2| N/A     | rat    | 1:200    | Southern Biotec|
| Goat anti-rabbit Alexa Fluor 594 | N/A     | IgG     | Goat   | 1:250    | Molecular Probes|
| Goat anti-mouse Alexa Fluor 488 | N/A     | IgG     | Goat   | 1:250    | Molecular Probes|
| Goat anti-rat Alexa Fluor 488 | N/A     | IgG     | Goat   | 1:250    | Molecular Probes|

doi:10.1371/journal.pone.0088172.t001
Table 2. Primers used for Real Time PCR.

| Primer Name | Primer Sequence | Primer Sequence | Product Size (bp) | Accession Numbers |
|-------------|----------------|----------------|-------------------|-------------------|
|             | (Forward 5'-3') | (Reverse 5'-3') |                   |                   |
| αSM actin   | AAGGCCAACCGGGAGAAAAAT | GATGGGGAATTTGAGTGGGA | 158 | NM_001613 |
| Collagen I (a) | ATGCTTGGTGAACTGCTTGT | CAGGTGCGCCGTCAGCAC | 285 | NM_000088 |
| CD34        | TTGACAAACGGTACTGCTAC | TGTTGAACACTGTGCGTATTAC | 270 | NM_001773 |
| Calponin    | CAGTGTGCAGACGGAACTCC | GCCGTCGATGAAATGTTGTC | 241 | NM_001299 |
| GAPDH       | ACCACGATGCCATGACCAC | TTCTAGACCGCAGGTAGTT | 225 | NM_002046 |

![Figure 1. Immunofluorescence staining of M+SMCs, M+Ps and Monocytes on day 14 of culture. M+SMCs: A) CD34 (red), B) Procollagen I (green), C) the expression of double staining of CD34 (red cell surface) and procollagen I (green cytoplasm), D) αSM actin and E) calponin (both green). M+Ps: F) CD34 (red), G) Procollagen I (green), H) positive expression of both CD34 and procollagen I (orange). I) αSM actin and J) calponin (both green). Monocytes: lack of expression of αSMC actin and calponin (K & L respectively). Positive controls: M) CD34 (red), N) Procollagen I (green), O) αSMC actin (green), P) Calponin (green). Isotype controls: (Q) rabbit IgG, (R) mouse IgG and (S) rat IgG. Nuclei of the cells are blue. Scale bars 100 μm. doi:10.1371/journal.pone.0088172.g001](attachment:Figure%201.png)
### Table 3. CD surface markers expressed by each cell type.

|                | Monocytes | Macrophages | Macrophage foam cells | M+SMCs | M+Ps |
|----------------|-----------|-------------|-----------------------|--------|------|
| **Monocytes**  |           |             |                       |        |      |
| CD71           | 16.21 fold (CI 9.57–27.46) |             |                       |        |      |
| CD54           | 14.2 fold (CI 7.37–27.36) |             |                       |        |      |
| CD254          | 13.51 fold (CI 6.15–29.69) |             |                       |        |      |
| CD9            | 5.64 fold (CI 3.53–9.01) |             |                       |        |      |
| **Macrophages** |           |             |                       |        |      |
| CD182          | 53.26 fold (CI 23.89–118.73) |             |                       |        |      |
| CD181          | 17.22 fold (CI 6.22–47.68) |             |                       |        |      |
| CD184          | 1.92 fold (CI 1.69–2.19) |             |                       |        |      |
| CD124          | 1.63 fold (CI 1.35–1.95) |             |                       |        |      |
| CD11c          | 1.59 fold (CI 1.42–1.76) |             |                       |        |      |
| **Macrophage foam cells** |           |             |                       |        |      |
| CD4            | 2.74 fold (CI 3.46–22.52) |             |                       |        |      |
| CD64           | 1.33 fold (CI 1.18–1.50) |             |                       |        |      |
| **M+SMCs**     |           |             |                       |        |      |
| CD38           | 4.36 fold (CI 2.41–7.90) |             |                       |        |      |
| CD182          | 56.43 fold (CI 20.22–157.49) |             |                       |        |      |
| CD254          | 16.54 fold (CI 12.83–40.81) |             |                       |        |      |
| CD81           | 22.88 fold (CI 12.83–40.81) |             |                       |        |      |
| CD281          | 1.95 fold (CI 1.59–2.39) |             |                       |        |      |
| CD71           | 16.6 fold (CI 5.38–51.11) |             |                       |        |      |
| **M+Ps**       |           |             |                       |        |      |
| CD52           | 55.5 fold (CI 14.35–214.63) |             |                       |        |      |
| CD254          | 6.4 fold (CI 6.14–43.83) |             |                       |        |      |
| CD11c          | 2.72 fold (CI 1.84–4.00) |             |                       |        |      |
| CD181          | 15.9 fold (CI 6.72–38.02) |             |                       |        |      |
| CD9            | 7.5 fold (CI 4.02–14.14) |             |                       |        |      |
| CD38           | 6.5 fold (CI 3.5–51.89) |             |                       |        |      |
| CD182          | 4.4 fold (CI 2.41–7.91) |             |                       |        |      |
| CD11a          | 4.32 fold (CI 3.15–5.12) |             |                       |        |      |
| CD5            | 5.76 fold (CI 10.34–32.1) |             |                       |        |      |
| CD61           | 2.34 fold (CI 1.7–3.2) |             |                       |        |      |
| CD10           | 19.94 fold (CI 6.05–41.96) |             |                       |        |      |
| CD37           | 17.13 fold (CI 6.29–46.67) |             |                       |        |      |
| CD40           | 11.86 fold (CI 6.13–22.95) |             |                       |        |      |
| CD2            | 7.67 fold (CI 3.56–16.52) |             |                       |        |      |
| CD16           | 4.60 fold (CI 3.49–6.06) |             |                       |        |      |
| CD11a          | 3.53 fold (CI 2.63–4.75) |             |                       |        |      |

The table records all the markers which were significantly (P<0.001) expressed by each cell type listed in the horizontal axis (bold font) when compared to the cell types listed in the vertical axis (italics font) with their associated 95% confidence intervals (CI). For example, monocytes expressed the marker CD182, 53.26 fold significantly higher than macrophages.

doi:10.1371/journal.pone.0088172.t003
The primary antibodies (Table 1) or isotype controls were incubated with the cells for 30 min at room temperature (RT) and washed gently with TBS three times. Three drops of secondary antibodies (Table 1) was then added for 60 minutes at RT after which the cells were washed again three times with TBS. When double staining was performed the second antibody was added for 30 minutes at RT after which the washing step was performed. Their respective secondary antibodies were then added for 60 minutes at RT after which the cells were washed again three times with TBS. All cultures were then stained with a 1/10,000 dilution of 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, Grand Island, NY, USA) in PBS for 10 minutes to allow visualization of the nuclei. The stained cells were mounted with aqueous fluorescent mounting media (DAKO, Sydney, Australia).

All staining was conducted with appropriate positive controls, KG1 leukaemic cell line [33,43] for CD34 and human umbilical smooth muscle cells [35,37] for all other markers.

**Image analysis.** Single stained cells were viewed with a Leica DMLB fluorescent microscope (Leica Microsystems, Sydney, Australia) and photos taken using a SPOT camera (RTK Electronic Instruments Inx, MI, USA). Double stained cells were observed under the Olympus 1x81 confocal microscope and Images acquired using the Olympus Fluorview FV1000 (Olympus Australia Pty Ltd, VIC, Australia).

**Quantitative PCR**

**qPCR protocol.** RNA was isolated using either the Absolutely RNA Nanoprep Kit (Stratagene, TX, USA) or the Qiagen RNeasy Minikit (Qiagen, Hilden, Germany). Total RNA was transcribed into cDNA using the Affinity Script kit (Stratagene, TX, USA). qPCR was performed using the Brilliant II Sybr Green kit (Stratagene, TX, USA) and samples were set up on the Stratagene MX 3005P. Controls containing all constituents except reverse transcriptase were performed to rule out contamination by DNA and all constituents except the template to rule out contamination of the reagents. Table 2 represents all the primers that were used.

**qPCR Analysis.** The Stratagene MxPro software determined the average copies of a gene from the duplicate samples which were then normalised against the reference gene GAPDH.

**Cluster of Differentiation (CD) Array**

A CD array, containing a panel of 148 antibodies and their respective isotype controls, was performed on monocytes, macrophages, macrophage foam cells, M+Ps and M+SMCs.

**Cell Culture**

**Monocytes.** WBCs were isolated from leukopaks (Australia Red Cross Blood Service, NSW, Australia) using the Lymphoprep™ 1.077 and monocytes obtained using the CD14 microbeads system.

**Macrophages and macrophage foam cells.** WBCs were isolated from leukopaks (Australia Red Cross Blood Service, NSW, Australia) using the Lymphoprep 1.077™. Macrophages and macrophage foam cells were generated as per the method described in Davies and Gordon 2005 [9].

**Macrophages.** WBCs were cultured with RPMI 1640 (Invitrogen, Grand Island, NY, USA) containing 7.5% donor plasma for 90 minutes at 37°C, 5% CO2. The cells were maintained in X- VIVO media (Lonza Australia Pty Ltd, Mt Waverly, VIC, Australia) with 1% donor plasma, media was changed on day 7 and macrophages harvested on day 10.

**Macrophage foam cells.** Macrophages were cultured as described above. On day 9, acetylated low density lipoprotein was added to the cultures at a concentration of 50 μg/mL of RPMI 1640 media containing 10% lipoprotein deficient serum and cultured for 2 days [4]. Foam cells were harvested on day 11 of culture.
M+P and M+SMCs. The cultured monocytes were set up as described above. On day 14 the cells were detached using Accutase (Millipore, CS, USA).

**Analysis of cell marker expression.** The cells were then prepared for CD array analysis by suspending them at a concentration of 0.4x10^7 cells/mL (as recommended in the manufacturer’s manual) in PBS containing 2% heat inactivated AB serum (Sigma-Aldrich, MO, USA). The cells were incubated on the array slides for 30 minutes (Medisac Pty Ltd, NSW, Australia) and fixed with 4% formaldehyde. Slides were then placed in the DotReader and scanned by the DotScan Software (Medsaic Pty Ltd, NSW, Australia). Once slides were scanned digital images were captured; after which the proportion of cells in the sample expressing the antigen as well as the level of expression was determined. Prior to statistical analysis each marker was normalised against CD44 as per the Medsaic protocol [14].

**Electron Microscopy Analysis**

Electron microscopy was used to assess the ultrastructural morphology of monocytes, M+Ps and M+SMCs. On days 1, 3, 5, 7, 10 and 14 of culture; the cells were fixed with 0.5ml Karnovsky’s fixative and resin embedded. Ultrathin sections were prepared (Leica EM UC6, Leica, Germany) and collected on 400m thin bar mesh copper grids (Proscitech, QLD, Australia). Each copper grid was stained with uranyl acetate solution (Sigma-Aldrich, MO, USA) and transferred to lead citrate, washed and allowed to dry prior to electron microscopy analysis. A CM 10 transmission electron microscope (Phillips, NSW, Australia) was used to analyse all stained samples and images were captured on Kodak Electron Microscopy Film 4489 (Holgate Scientific Pty Ltd, NSW, Australia). A minimum of 30 cells from 2 different sections were analysed for each sample.

**Figure 3.** Electron microscopy analysis of M+SMCs and M+Ps. M+SMCs. Figure A) Day 7 of culture containing ribosomes (arrows) (B). Figure C) Day 10 of culture with microfilaments* surrounded by lysosomes (Ly) (D) and present closer to the nucleus (E) M+Ps Figure F) Day 7 culture containing microfilaments* (G). H) Day 10 culture containing microfilaments* surrounded by monoribosomes (arrows) (I). Figure J) Day 5, containing rough endoplasmic reticulum (rER) with ribosomes attached (small electron dense beads) (arrows) and day 14 cells showing rER with average length of 1.9 µm (Figure K). Monocytes Figure L) Day 14 culture with the presence of autophagy (A) and a nucleus (N).

doi:10.1371/journal.pone.0088172.g003
Statistical Analysis

All statistical analysis were performed using the Statistical Product and Service Solutions Version 17 (SPSS Inc, Chicago, USA) (SPSS).

qPCR statistical analysis: GAPDH was used to normalize the data and differences were analysed using the Student’s T Test. All tests were two-tailed and differences were considered to be significant, *P<0.05. Expression of fold increases in gene expression was analysed by comparing the M+P or M+SMCs against the monocytes.

CD Array statistical analysis: All data were analysed using the two-tailed tests. The expression levels were log transformed to approximate normality prior to analysis. Analysis of variance was used to test for heterogeneity in log expression levels for each cell surface marker in each cell type. To place the highest stringency on the analysis of the data P<0.001 was chosen. This p value ensures that any cell surface markers that are significant would be 99.9% assured.

Results

Expression of Markers by M+SMCs, M+Ps and Cultured Monocytes by Immunofluorescence and CD Array

To study the differentiation potential of monocytes into smooth muscle like cells, monocytes were co-cultured with platelets or HcaSMCs and analysed for cell marker expression. The M+SMCs co-expressed CD34 and procollagen I (Figure 1C), αSM actin (Figure 1D) from day 7 onwards and calponin from day 14 (Figure 1E). The M+Ps co-expressed CD34 and procollagen I (Figure 1F) from day 7 onwards, whilst the SMC markers; αSM actin (Figure 1G) and calponin (Figure 1H) were expressed from day 14 onwards. Monocytes cultured without SMCs or platelets did not express any of the SMC markers (Figure 1K&L).

Analysis by CD array of surface markers identified a number of significant differences between the co-cultured cells and those cells typically found in atherosclerotic plaques. A comparison of M+SMC to monocytes, macrophages and foam cells found that M+SMC could be distinguished from monocytes by their significantly lower levels of CD38 and CD182; from macrophages by their significantly lower levels of CD81 and CD254 and from foam cells by their significantly lower levels of CD61, CD81, CD269 and CD281. A comparison of M+Ps found that these cells could be distinguished from monocytes by their significantly lower levels of CD11a, CD33, CD38, CD52, CD95, CD181, CD182, and their significantly higher levels of CD29 and CD71; from macrophages by their significantly lower levels of CD11a, CD11c and CD254 and from foam cells by significantly lower levels of CD2, CD10, CD11a, CD16, CD22, CD33, CD37, CD40, CD45RA, CD281 and significantly higher levels of CD5. Table 3 represents the statistically significant marker expression of each cell when compared to one another. There were no significant marker differences between M+SMC and M+P cells. When comparing the co-cultured monocytes with monocytes, macrophages and foam cells the results showed that the co-cultured monocytes expressed the myeloid markers including CD14 and CD45 at levels that were not significantly different to monocytes, macrophages and foam cells.

Expression of Markers by M+SMCs, M+Ps and Cultured Monocytes by qPCR

qPCR was used to examine the level of gene expression in the co-cultures M+P and M+SMCs as compared to monocytes.

M+SMCs (Figure 2A). Although not significant there was an increase in αSM actin marker of 1.07 fold (P = 0.53) and 1.19 fold (P = 0.63) on days 7 and 14 respectively. This same increase was also found in collagen I by 1.64 fold (P = 0.47) and 6.34 fold (P = 0.2) on day 7 and 14 respectively. In terms of expression there was a 10.5 fold (P = 0.003) increase of Calponin expression and a 2.25 significant fold (P = 0.005) increase in the expression of CD34. This was reflected in co-cultured monocytes and occurred on day 14.

M+Ps (Figure 2B). There was an increase in αSM actin of 1.33 fold (P = 0.47), significantly greater level of expression of calponin of 18.9 fold (P = 0.03) and CD34 of 2.16 fold (P = 0.1) on day 14. Although not significant, the level of expression of collagen I was greater in co-cultured monocytes on both day 7 at 4.03 fold (P = 0.48) and day 14 at 1.11 fold (P = 0.9) when compared to monocytes cultured alone.

Differences in Phenotypic Analysis Comparing M+SMCs and M+Ps from Cultured Monocytes

All cell types were seen to develop azurophilic granules, vacuoles, lysosomes, all had phagocytic abilities and lost their fingerlike projections from day 3 of culture.

The cells generated from M+SMCs cultures were found to have increases in the number of short profiles of rough endoplasmic reticulum (rER) within the cytoplasm of the cells with a length of approximately 0.8 μm on day 7 (Figures 3A&B). On day 10, microfilaments were found in the elongated regions of the cells (Figures 3C-E). The cells generated from M+Ps cultures were found to contain small short rER with an average length of 0.8 μm from day 5 (Figure 3F) and had elongated to an average of 1.9 μm in length by day 14 of culture (Figure 3G). On day 7, small bundles of microfilaments made up of parallel filaments were observed (Figure 3F&G). These were more evident in the cell cytoplasm and located at the elongated region of the cell accompanied by numerous monoribosomes on day 10 (Figure 3H&I).

Three differences were identified between cultured and co-cultured monocytes which indicated that the co-cultured cells had differentiated: Firstly, there was an increase in rER observed in the co-cultured monocytes. Secondly, the co-cultured cells showed the presence of microfilaments. Thirdly, there was the absence of autophagy which was observed only in the monocytes alone (Figure 1L). The increase in the number of rER and the presence of microfilaments located distally from the nucleus within the elongated regions are characteristics of myofibroblasts and fibroblasts.

Discussion

The role of monocytes in the formation of foam cells in atherosclerosis has been well documented [18]. More recently, the pluripotent nature of monocytes has been reported. This is the first study to report that monocytes in an atherosclerotic setting, when co-cultured with SMCs or platelets further differentiated into cells expressing both fibroblast and myofibroblast characteristics as determined by immunofluorescence, qPCR, CD array and electron microscopy.

For this study a culture model was established as per Abe 2001 [1] where platelets or HcaSMCs were placed in a 0.4 μm Transwell. This Transwell size was selected to ensure that the platelets (13–27 cubic μm [27]) or HcaSMCs (100 μm in length and 5–10 μm in width [39]) could not pass through the Transwell pores into the culture well containing the monocytes. This Transwell model was setup as initial experiments where SMC or platelet conditioned media was cultured with monocytes were found not to induce SMC marker expression (data not shown). This finding suggests that an ongoing release of cytokines by SMCs
and platelets (PDGFβB, TGFβ1, EGF, VEGF, bFGF and IGF) [0,24,29] is required to induce differentiation in these two models.

Immunofluorescence and qPCR data found CD34 and the markers: SM actin, collagen I and calponin were expressed by cells in both co-culture systems. All these markers were expressed at levels greater than cultured monocytes as determined by qPCR. The following markers were chosen for the following reasons: SM actin forms part of the cytoskeleton, plays an essential role in regulating cell movement associated with SMCs [28] and has been used as a marker for SMCs [30]. Collagen I functions to provide the scaffolding and support for a wound during the processes of wound healing [11]. It is needed for the repair of the anatomic structure, strength and function of the injured tissue [36]. Calponin is involved in cell contraction, by inducing actin filament bundling leading to contraction and it is an identifying marker of SMCs [30]. Interestingly, the expression of CD34 by immunofluorescence staining was observed from day 7 in all culture conditions even though mRNA was not detected until day 14 via qPCR. Reports in the literature have noted that low/undetectable levels of mRNA with protein expression can occur [17] and that mRNA can be stored in the nucleus and only released once protein levels have reached a threshold limit [34].

Unexpected observations were found: cultured monocytes expressed both CD34 and Collagen I. These findings are in agreement with Curnow 2010 [7] who also reported that monocytes cultured in serum media expressed these markers. Immunofluorescence and qPCR results show that cultured monocytes differentiate into fibrocytes (co expression of CD34 and collagen I) irrespective of culture conditions. The findings reveal that the addition of SMCs or platelets promotes further differentiation into SM like cells.

Additional cell surface marker analysis by CD array showed that M4+SMCs and M4+Ps could be distinguished from their precursor the monocyte, macrophages and macrophage foam cells. Notably, these cells did not express markers known to be involved in the process of atherosclerotic plaque progression by their significant lower expression of CD254 and CD281 when compared to macrophages and foam cells respectively. The expression of CD254 is associated with calcification and plaque rupture [2] and CD281 (Toll- like receptor-1) reflect the active state of macrophages or foam cells in phagocytosing foreign particles like lipid in the area of atherosclerosis. These markers are found predominantly in areas of damaged endothelium and high inflammatory cell localisation in atherosclerotic plaques where macrophages foam cells reside. The CD array results indicated that the SMCs and platelets provide an environment which enables the monocytes to start differentiating into cells that do not play a role in plaque instability.

Phenotype analysis was conducted using EM. The co-cultured monocytes identified that our cells contained increased numbers of rER indicating a higher level of protein synthesis, characteristic of a myofibroblast/fibroblast [16]. Microfilaments/actin filaments located within the elongated regions of the co-cultured cells are indicative of locomotive. These filaments could function to enable the cell to move around their environment to search and endocytose foreign material in the blood or in tissues for elimination. These two features were not found in cultured monocytes.

These two features are therefore suggestive of a fibroblast cell type, classed as a SM like cell. Our co-cultured monocytes were not representative of mature SMCs as they lacked dense bodies and abundant mitochondria, did not contain myofilaments and contained few filament bundles. They were also not typical myofibroblasts by the absence of the myofilaments as well as fibronexus [42]. The literature reports that mesenchymal cells have similar markers to fibroblasts with many overlapping markers [12]. The increased amounts of microfilaments, rER and the expression of fibroblast markers CD29 and CD81 reported by the CD array is supporting evidence that the co-cultured monocytes have differentiated into a mesenchymal/fibroblast like cell.

The significance of this work shows the capability of a circulating blood monocyte to differentiate into a cell that expresses markers including SM actin and CD45. These findings are in agreement with a number of in vivo studies showing that circulating progenitor cells expressing SM actin and CD45 are extensively recruited in a variety of atherosclerotic injury models [32,40,41]. The SM actin+ CD45+ cells in these models were located in the neointimal regions of the injury. These studies support the potential of the cells generated in our model to be involved in atherosclerotic plaques and fibrous cap formation. Further studies are needed to show that circulating monocytes have the ability to localise in atherosclerotic plaques and are able to form fibrous plaques in an in vivo model.

In both co-culture systems the environmental conditions provided by the SMCs and platelets resulted in the differentiation of monocytes to SM like cells with mesenchymal/fibroblastic like characteristics. These cells do maintain their myeloid lineage by their marker expression of CD14 but they also expressed collagen I, SM actin and calponin (found in SMCs) with the additional phenotypic changes. Although CD14 expression is reported to decrease as monocytes mature, it has also been reported that maturing monocytes can maintain their levels of CD14 expression [46] whilst tumour necrosis factor, interleukin -1 and 6 moderately increases CD14 [21,31]. These studies demonstrate that maturing monocytes can maintain or increase their level of CD14 expression as per the cytokines they were exposed to. Future studies analysing the culture environment provided by the platelets or SMCs would identify the cytokines present in these models. These results support the idea that monocytes in atherosclerosis may be induced to play a greater role in plaque stability. In future studies, the functional and further differentiation abilities of these cells and how these co-cultured cells differ from one another would be determined to consolidate this data.

Acknowledgments

The authors would like to thank Dr Shane Thomas from the Centre of Vascular Research, UNSW, NSW, Australia for kindly donating HcaSMC for this study, Karen Byth and Kerry Hitoz for their assistance with the statistical analysis in the qPCR and CD array analysis.

Author Contributions

Conceived and designed the experiments: MWYW AKG. Performed the experiments: MWYW. Analyzed the data: MWYW AKG. Contributed reagents/materials/analysis tools: MWYW AKG. JPF. Wrote the paper: MWYW AKG.

References

1. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN (2001) Peripheral blood monocytes differentiate into SM like cells. J Immunol 166: 7356-62.

2. Antonov AS, Kolodgie FD, Munn DH, Gerrity RG (2004) Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am J Pathol 165: 247-250.
3. Bina N, O'Reilly S, Grifflitis B, van Loar JM, Hugle T (2012) Differentiation Potential of CD14+Monocytes into Myofibroblasts in Patients with Systemic Sclerosis. PLoS ONE 7: e33508.

4. Brown BE, Rashid I, van Reyk DM, Davies MJ (2007) Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesterol esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. Faseb J 21: 1530–1541.

5. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Molecular Medicine 1: 71–81.

6. Clanchy FIL, Holloway AC, Lari R, Cameron PU, Hamilton JA (2006) Detection and properties of the human proliferative monocyte subpopulation. Journal of Leukocyte Biology 79: 1–10.

7. Curnow SJ, Fairclough M, Schmutz C, Kissane S, Denniston AK et al (2010) Distinct types of fibrocyte can differentiate from mononuclear cells in the presence and absence of serum. PLoS One 5: e3730.

8. Daridk A, Yamashita A, Aziz F, Asada H, Sumpio BE (2005) Shear stress-stimulated endothelial cells induce smooth muscle cell chemotaxis via platelet-derived growth factor-β and IL-1α. J Vasc Surg 41: 321–331.

9. Davies JQ, Gordon S (2005) Isolation and culture of human macrophages. Methods in Molecular Biology 290: 105–116.

10. Desmouliere A, Chaponnier C, Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13: 7–12.

11. Diegelmam RF, Evans MC (2004) Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 9: 283–299.

12. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317.

13. Dotenko O (2010) Stem/Progenitor Cells, Atherosclerosis and Cardiovascular Regeneration. Open Cardiovasc Med J 4: 97–104.

14. Ellmark P, Belov L, Huang P, Lee CS, Solomon M.J et al. (2006) Multiplex Definition Useful in Diagnosis and Research. Ultrastructural Pathology 25: 39–50.

15. Eppley BL, Woodell JE, Higgins J (2004) Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plastic and Reconstructive Surgery 114: 1502–1508.

16. Eyden B (2001) The Myofibroblast: An Assessment of Controversial Issues and a Role for Ggc1 in Cellular sensitivity to rapamycin. Mol Cell Proteomics 9: 371–384.

17. Fournier ML, Paulown A, Pavelka N, Molesy AL, Gaudenz K et al. (2010) Delayed correlation of mRNA and protein expression in rapamycin-treated cells and a role for Ggc1 in cellular sensitivity to rapamycin. Med Cell Proteomics 9: 271–284.

18. Goldberg DR, Gordon S (2009) The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res 50 Suppl: S282–S286.

19. Kodama H, Inoue T, Watanabe R, Yasuoka H, Kawakami Y et al. (2005) Cardiomyogenic potential of mesenchymal progenitors derived from human circulating CD14+ monocytes. Stem cell and Development 14: 676–686.

20. Kodama H, Inoue T, Watanabe R, Yasutomi D, Kawakami Y, et al. (2006) Neurogenic potential of progenitors derived from human circulating CD14+ monocytes. Immunology and Cell Biology 84: 209–217.

21. Lauener RP, Goyert SM, Ghez RS, Vercelli D. (1990) Interleukin 4 down-regulates the expression of CD4 in normal human monocytes. Eur J Immunol 20: 2375–2381.

22. Li ZY, Howarth SPS, Tang T, Gillard JH (2006) How Critical Is Fibrous Cap Thickness to Carotid Plaque Stability?: A Flow-Plaque Interaction Model. Stroke 37: 1195–1199.

23. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91: 2844–2850.

24. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kanate C et al. (2001) Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89: 930–934.

25. Medbury HJ, Tarran SL, Guiffre AK, Williams MM, Lam TH et al. (2008) Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes. International Angiology 27: 114–123.

26. Medina A, Brown E, Carr N, Ghahary A (2009) Circulating monocytes have the capacity to be transdifferentiated into keratinocyte-like cells. Wound Repair and Regeneration 17: 268–277.

27. Paulus JM (1975) Platelet size in man. Blood 46: 321–336.

28. Reddy S, Ozgor K, Lu M, Chang W, Mohan SR et al. (1998) Structure of the human smooth muscle alpha-actin gene. Analysis of a cDNA and 5′ upstream region. Journal of Biological Chemistry 263: 1683–1687.

29. Rendu F, Bredhah-Bohn B (2001) The platelet release reaction: granules’ constituents, secretion and functions. Platelets 12: 261–273.

30. Rose JJ, Hong Z, Willhalm B, Zeng L, Iacobell B et al. (2006) Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. Journal of Clinical Investigation 116: 3139–3149.

31. Ruppert J, Friedrichs D, Xu H, Peters JH (1991) IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Immunobiology 182: 449–464.

32. Sata M, Sairia A, Kuniato A, Tojo A, Okada S et al. (2002) Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8: 403–409.

33. Sato H, Kurosawa A, Ueda J, Takano K, Nakamura T et al. (2010) Characterization of smooth muscle-like cells in circulating human peripheral blood mononuclear cells. Circulation 122: 54–62.

34. Swirski FK (2011) The spatial and developmental relationships in the macrophage family. Arterioscler Thromb Vasc Biol 31: 1517–1522.

35. Tanaka Y, Meera P, Song M, Knaus NG, Toro L (1997) Molecular constituents of macro K+Ca channels in human coronary smooth muscle: predominant alpha+ beta subunit complexes. J Physiol 502: 545–557.

36. Tanaka K, Sata M, Hirata Y, Nagai R (2003) Diverse contribution of bone marrow to plaque stability: A Flow-Plaque Interaction Model. Circulation 107: 718–725.

37. Sugiyama S, Kugiyama K, Nakamura S, Kataoka K, Aikawa M et al. (2006) Characterization of smooth muscle-like cells in circulating human peripheral blood mononuclear cells. Blood 106: 1289–1299.

38. Torsney E, Mandal K, Halliday A, Jahangiri M, Xu Q (2007) Characterisation of monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Immunobiology 182: 449–464.

39. Utevsky BR, Broun R, Tenen DG (1990) Regulation of the gene for CD34, a human hematopoietic stem cell antigen, in KG-1 cells. Blood 75: 2299–2304.

40. Wach PRO, de Graaf, DG, Goossens K, Pedman L, Jacobs FJ (2006) Differentiation gene expression in the honeybee head after a bacterial challenge. Dev Comp Immunol 32: 883–889.

41. Wiberg S, Rasmussen A, Bendtsen F, Gallucci S, Padrini A et al. (2007) Characterization of smooth muscle-like cells in circulating human peripheral blood mononuclear cells. Blood 107: 2845–2851.

42. Yen WH, Park J, Jung W, Ryu J, Park J et al. (2006) Characterisation of smooth muscle-like cells in circulating human peripheral blood mononuclear cells. Blood 107: 2845–2851.

43. Torsney E, Mandal K, Halliday A, Jahangiri M, Xu Q (2007) Characterisation of progenitor cells in human atherosclerotic vessels. Atherosclerosis 191: 259–264.

44. Yang H, Zhang R, Mu H, Li M, Yao Q et al. (2006) Adiponectin promotes endothelial cell differentiation from human peripheral CD14+ monocytes in vitro. Journal of Cell and Molecular Medicine 10: 459–469.

45. Zhao Y, Glese D, Huberman E (2003) A human peripheral blood monocyte-derived subset act as a pluripotent stem cells. Proc Natl Acad Sci USA 100: 2426–2431.

46. Ziegler-Heitbrock HW, Ulevitch RJ (1993) CD14: cell surface receptor and accessory potency. Immunobiology 182: 449–464.